Yeon Joo Kim1, Si Yeol Song2, Wanlim Kim3, Jongseok Lee3, Jin-Hee Ahn4, Jeong Eun Kim4, Hye Won Chung5, Seong-Yun Jeong6, Eun Kyung Choi1. 1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; siyeol.song@gmail.com. 3. Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 5. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 6. Asan Cancer Institute, Seoul, Republic of Korea.
Abstract
BACKGROUND/AIM: To compare absolute volume (AV) assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) for the response evaluation of desmoid tumors (DTs) treated with radiotherapy. PATIENTS AND METHODS: Eighteen patients with DTs ≥3 cm in size were included. RESULTS: The median follow-up duration was 78.0 months. Five patients achieved a complete response according to RECIST, seven reached a partial response (PR), and one eventually exhibited progression. The overall response rate was 61%, the median time to PR was 8.0 months. Six patients achieved stable disease, although three developed progressions. Of the six patients with a PR, the median change in maximum diameter was -46%, and the median change in maximum volume was -84%. Three patients could have been diagnosed with progression at least 6 months earlier if the AV increment was considered. CONCLUSION: An AV assessment is essential for an accurate response assessment of DTs and radiotherapy seems feasible as a first-line treatment for DTs. Copyright
BACKGROUND/AIM: To compare absolute volume (AV) assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) for the response evaluation of desmoid tumors (DTs) treated with radiotherapy. PATIENTS AND METHODS: Eighteen patients with DTs ≥3 cm in size were included. RESULTS: The median follow-up duration was 78.0 months. Five patients achieved a complete response according to RECIST, seven reached a partial response (PR), and one eventually exhibited progression. The overall response rate was 61%, the median time to PR was 8.0 months. Six patients achieved stable disease, although three developed progressions. Of the six patients with a PR, the median change in maximum diameter was -46%, and the median change in maximum volume was -84%. Three patients could have been diagnosed with progression at least 6 months earlier if the AV increment was considered. CONCLUSION: An AV assessment is essential for an accurate response assessment of DTs and radiotherapy seems feasible as a first-line treatment for DTs. Copyright
Authors: Sylvie Bonvalot; Nils Ternès; Marco Fiore; Georgina Bitsakou; Chiara Colombo; Charles Honoré; Andrea Marrari; Axel Le Cesne; Federica Perrone; Ariane Dunant; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2013-09-20 Impact factor: 5.344
Authors: Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz Journal: N Engl J Med Date: 2018-12-20 Impact factor: 91.245
Authors: M A Spear; L C Jennings; H J Mankin; I J Spiro; D S Springfield; M C Gebhardt; A E Rosenberg; J T Efird; H D Suit Journal: Int J Radiat Oncol Biol Phys Date: 1998-02-01 Impact factor: 7.038
Authors: Reineke A Schoot; Kieran McHugh; Rick R van Rijn; Leontien C M Kremer; Julia C Chisholm; Huib N Caron; Johannes H M Merks Journal: Radiology Date: 2013-10-28 Impact factor: 11.105